Total cholesterol/high-density lipoprotein and inflammatory parameters in patients with polycystic ovary syndrome

Abstract

OBJECTIVE: In this study, the hormone profile, lipid profile, and inflammatory parameters of patients with polycystic ovary syndrome were compared with those of non-polycystic ovary syndrome patients to determine predictive markers in young polycystic ovary syndrome patients who have not yet had children. METHODS: Patients' age, height, weight, body mass index, waist circumference, degree of hirsutism, and ultrasound findings were recorded. Hormone profile, lipid levels, ratio of complete blood count parameters, monocyte/high-density lipoprotein ratio, and total cholesterol/high-density lipoprotein ratio were compared between groups. RESULTS: No statistically significant differences were found between groups in terms of age, weight, waist circumference, body mass index, and dysmenorrhea (p>0.05). A significant relationship was found between the height and the degree of hirsutism in the groups (p<0.05). It was found that prolactin, total testosterone, and dehydroepiandrosterone sulfate levels were statistically significantly higher in the polycystic ovary syndrome group compared to the control group. The polycystic ovary syndrome group had hemoglobin, leukocytes, lymphocytes, neutrophils, platelets, and statistically higher ratios of total cholesterol/high-density lipoprotein, Low-density lipoprotein/high-density lipoprotein, and triglycerides/highdensity lipoprotein. No statistically significant relationships were found between homeostatic model assessment insulin resistance, neutrophilto-lymphocyte ratio, and monocyte-to-high-density lipoprotein ratio between the groups (p<0.05). There was no significant difference in systemic immune inflammation index values between the groups. CONCLUSION: Polycystic ovary syndrome patients are at risk for short-and long-term complications, and the use of the total cholesterol/high-density lipoprotein, Low-density lipoprotein/high-density lipoprotein, and triglycerides/high-density lipoprotein ratios in clinical practice during the follow-up of these patients may allow easy follow-up for patients. The health status of polycystic ovary syndrome patients can be objectively determined by tracking these outcomes at regular intervals.

Association between lower urinary tract symptoms and polycystic ovary syndrome

“…Patients often present with ovulation problems such as menstrual irregularities or infertility. Other clinical implications include endothelial damage, obesity, insulin resistance, and hyperandrogenism, which are closely associated with inflammatory processes in the pathogenetic pathways of PCOS 1 . For healthy maintenance of voiding physiology, anatomic factors must be in perfect harmony with neuroendocrine pathways.…”

“…Accordingly, a waist circumference of 88 cm and above were classified as high risk. Hirsutism is assessed with the modified Ferriman–Gallwey score (mFG) 1 . The extent of lower urinary tract symptoms in each case included in the study was analyzed using the Bristol Female Lower Urinary Tract Symptom (BFLUTS) questionnaire.…”

“…Polycystic ovary syndrome (PCOS) is an endocrinological disorder that occurs in women of reproductive age 1 . Approximately 6–20% of women in this period are affected.…”

“…Lower urinary tract symptoms (LUTS) are characterized by three main symptoms 1 : storage symptoms, such as urgency, frequency, nocturia, and urge incontinence 2 ; voiding symptoms, such as poor and/or intermittent stream; and 3 post-voiding symptoms, such as the feeling of incomplete emptying 5 . LUTS exceeds the critical threshold, quality of life is impaired, level of physical activity is decreased, and psychological condition is negatively affected 6 .…”